Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Sernova Corp T.SVA

Alternate Symbol(s):  SEOVF

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a... see more

TSX:SVA - Post Discussion

Sernova Corp > Thoughts on this?
View:
Post by Treesh on Nov 27, 2021 1:52pm

Thoughts on this?

Posted by Camilo Ricordi this morning:

“It’s a remarkable time for T1D research efforts worldwide as this investigational treatment enters the clinic,” said Camillo Ricordi, M.D., Professor of Surgery, Director of the Diabetes Research Institute and the Cell Transplant Center at the University of Miami Miller School of Medicine, Steering Committee Chair for the VX-880 clinical trial and Principal Investigator at the University of Miami Health System clinical site. “The field’s experience with the limited cadaveric islet transplants available, where some patients have experienced prolonged insulin independence for years, provides important proof-of-concept for the potential of cell therapy to be transformative for patients living with T1D.”
 
Mr. Shelton was the first patient. On June 29, he got an infusion of cells, grown from stem cells but just like the insulin-producing pancreas cells his body lacked.
 
Now his body automatically controls its insulin and blood sugar levels.
 
Mr. Shelton, now 64, may be the first person cured of the disease with a new treatment that has experts daring to hope that help may be coming for many of the 1.5 million Americans suffering from Type 1 diabetes.
 
“It’s a whole new life,” Mr. Shelton said. “It’s like a miracle.”
 
This was first base to possibly solve the challenge of developing an unlimited supply of insulin producing cells … now if you combine it with a technology that could eliminate the need for chronic immunosuppression of the recipients (www.iTolerance.com) and we could have the long waited home run - Camillo Ricordi
 
Now more than ever, let’s keep focused on a biologic cure without anti rejection drugs !!!  
 
https://www.nytimes.com/2021/11/27/health/diabetes-cure-stem-cells.html?referringSource=articleShare
 
#diabetes #cure #diabetesresearch #stemcell #stemcelltherapy
Comment by BioTeck on Nov 27, 2021 4:49pm
We talked about this in this thread. Only difference from Edmonton protocol is that they used stem cells vs cadaver pancreatic cells.
Comment by Ekenbullets on Nov 28, 2021 3:58am
This news have exploded in the diabetes communicaties around the world. They are much better in creating publicity. 
Comment by Redbaron2211 on Nov 28, 2021 2:19pm
Who doesn't have working IPSC cells these days we all know dumping them in the portal vein is not the answer.  Was looking into Sana the other day, yet another example of a promising cell line however they plan on injecting into the pancreas.   How do they remove these cells if problems arise?  After the recent fatality it's clearly better to have the cells in a vascularized ...more  
Comment by BioTeck on Nov 28, 2021 3:56pm
Pharma can't be that blind. If sernovas tech was as useful as we are led to believe we wouldn't have troubles finding a partner. Do you not find it unusual that all these multi billion dollar companies are ignoring sernova? If nothing happens soon I think this company is going to be in trouble. Spillup needs to go.
Comment by Metalsguy1 on Nov 28, 2021 10:50pm
Spillup and the entire Board need to go. Big pharma must have a reason for ignoring Sernova. Aside from that IR at Sernova is utterly incompetent. They keep pulling feathers out of their a$$ and expecting the market to gasp in excitement.
Comment by Redbaron2211 on Nov 28, 2021 11:44pm
I feel Philip should be more conseratvie with estimates or at least realistic. I'm sure it feels close but the M & A process can really drag on.  Big pharma would be completing their M&A due diligence by these multiple collaborations.   Assuming the due diligence is completed the next step forward would be executing a final contract for sale. It can take a few ...more  
Comment by Metalsguy1 on Nov 29, 2021 12:16am
Redbaron, I am amazed at your tenacious death grip on those rose colored glasses. M&A only drags on when one or both parties are incompetent. There have been at least two companies that Ray Matthews touted around the investors as examples of how quickly a deal could happen. In one case it was a mere 72 hours between introduction and a buyout offer. Sure some deals take a long time to iron out ...more  
Comment by Redbaron2211 on Nov 29, 2021 12:35am
I have seen a number of examples of small acquisitions taking over a year.   Agree a simple acquisition could happen much quicker especially in a mature market.  This is an emerging market and there are more risks and as a result the DD has more depth.  Preclinical studies take time it's simply not going to happen quicker than a year IMO.  Since it's likely a licensing ...more